NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects

Journal of Viral Hepatitis

Volumn 23, Issue 11, 2016, Pages 840-849

  Vidal, L L ^a   Soares, M A ^a,b   Santos, A F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

drug resistance; genetic barrier; hepatitis C virus; NS3; protease inhibitor

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; FALDAPREVIR; NONSTRUCTURAL PROTEIN 3; PARITAPREVIR; SIMEPREVIR; TELAPREVIR; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CODON; GENE FREQUENCY; GENETIC ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; VIRAL GENETICS; VIRUS IDENTIFICATION; VIRUS STRAIN; AMINO ACID SUBSTITUTION; CHRONIC HEPATITIS C; CLASSIFICATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPACIVIRUS; MISSENSE MUTATION; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84993949847     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12503     Document Type: Review

References (56)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345(1): 41–52.
2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 47–52.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958–965.
4. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352(9138): 1426–1432.
5. Gaudieri S, Rauch A, Pfafferott K et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49(4): 1069–1082.
6. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55(1): 192–206.
7. Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol. Hepatol. (NY) 2011; 7(3): 154–162.
8. Lin K. Development of novel antiviral therapies for hepatitis C virus. Virol Sin. 2010; 25(4): 246–266.
9. Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci USA 2010; 107(49): 20986–20991.
10. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl 1): i36–i46.
11. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195–1206.
12. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405–2416.
13. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364(25): 2417–2428.
14. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207–1217.
15. Health USNIo, 2013.
16. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33(Suppl 1): 80–84.
17. De Meyer S, Ghys A, Foster GR et al. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 2013; 20(6): 395–403.
18. Foster GR, Hezode C, Bronowicki JP et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141(3): 881–889.
19. Silva MO, Treitel M, Graham DJ et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol 2013; 59(1): 31–37.
20. Cento V, Landonio S, De Luca F et al. A boceprevir failure in a patient infected with HCV genotype 1 g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy. Antivir Ther 2013; 18(4): 645–648.
21. Moreno C, Berg T, Tanwandee T et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56(6): 1247–1253.
22. Lenz O, Verbinnen T, Lin TI et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54(5): 1878–1887.
23. Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50(6): 1709–1718.
24. Cento V, Mirabelli C, Salpini R et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012; 7(7): e39652.
25. Kieffer TL, De Meyer S, Bartels DJ et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012; 7(4): e34372.
26. Palanisamy N, Danielsson A, Kokkula C et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013; 99(1): 12–17.
27. Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol 2012; 50(10): 3267–3274.
28. Lagace L, White PW, Bousquet C et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother 2012; 56(1): 569–572.
29. McPhee F, Friborg J, Levine S et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012; 56(7): 3670–3681.
30. McPhee F, Sheaffer AK, Friborg J et al. Preclinical profile and characterization of the hepatitis C VIRUS NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56(10): 5387–5396.
31. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012; 20(4): 139–145.
32. Wyles DL. Hepatitis C virus drug resistance: implications for clinical management. Infect Dis Clin North Am 2012; 26(4): 967–978.
33. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl 1): S88–S100.
34. Porcuna NC, Estévez MA, Ruiz JP, Quero JH, García FG. Actualización en la terapia de la hepatitis C. Nuevos fármacos, monitorización de la respuesta y resistencias. Enferm Infecc Microbiol Clin 2012; 31(1): 40–47.
35. Mani N. Clinically relevant HCV drug resistance mutations. Ann Forum Collab HIV Res 2012; 14.
36. Vidal LL, Santos AF, Soares MA. Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage. J Antimicrob Chemother 2015; 70(7): 2024–2027.
37. van de Vijver DA, Wensing AM, Angarano G et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41(3): 352–360.
38. Ribeiro JO, Oliveira RS, Hallal RC. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções, 2011.
39. Puri P, Anand AC, Saraswat VA et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. J Clin Exp Hepatol 2014; 4(2): 117–140.
40. Benhamou Y, Moussalli J, Ratziu V et al. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013; 208(6): 1000–1007.
41. Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl 1): 146–150.
42. Jensen DM, Wedemeyer H, Herring RW et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in Hcv Gt 1/4 patients treated with Rg7128 Plus Pegifn Alfa-2a (40kd)/Rbv: planned week 12 interim analysis from the propel study. Hepatology 2010; 52(4): 360a–361a.
43. Welsch C, Schweizer S, Shimakami T et al. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob Agents Chemother 2012; 56(4): 1907–1915.
44. Sanford M. Simeprevir: a review of its use in patients with chronic hepatitis C virus infection. Drugs 2015; 75(2): 183–196.
45. Thibeault D, Bousquet C, Gingras R et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 2004; 78(14): 7352–7359.
46. Lawitz E, Sullivan G, Rodriguez-Torres M et al. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 2015; 70(2): 197–205.
47. Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull 2015; 113(1): 31–44.
48. Dore GJ, Lawitz E, Hezode C et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015; 148(2): 355–366.
49. Sullivan JC, De Meyer S, Bartels DJ et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57(2): 221–229.
50. Powdrill MH, Tchesnokov EP, Kozak RA et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 2011; 108(51): 20509–20513.
51. Barnard RJ, McHale CM, Newhard W et al. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology 2013; 443(2): 278–284.
52. Flint M, Mullen S, Deatly AM et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 2009; 53(2): 401–411.
53. Chase R, Skelton A, Xia E et al. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res 2009; 84(2): 178–184.
54. Krishnan P, Tripathi R, Schnell G et al. Resistance analysis of baseline and treatment-emergent variants in the AVIATOR study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1. Antimicrob Agents Chemother 2015; 59(9): 5445–5454.
55. Pilot-Matias T, Tripathi R, Cohen D et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 2015; 59(2): 988–997.
56. Susser S, Vermehren J, Forestier N et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52(4): 321–327.